China Biotech Services Holdings Limited provided consolidated earnings guidance for the year ended 31 December 2023. For the period, Group expected to record a net loss attributable to the owners of the Company of approximately HKD 90,000,000. In contrast to the Loss, the Group recorded a net profit attributable to the owners of the Company of approximately HKD 258,087,000 for the corresponding period in 2022.